Sandra Romero-Cordoba
Overview
Explore the profile of Sandra Romero-Cordoba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
797
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romero-Cordoba S, Chirinos M, Noyola-Martinez N, Torres-Ramirez N, Garcia-Olivares M, Aragon-Hernandez J, et al.
Mol Cell Endocrinol
. 2023 Oct;
579:112088.
PMID: 37832930
Calcitriol and transforming growth factor beta 1 (TGF-β1) are unrelated molecules that regulate biological processes according to the genetic target, cell type, and context. Several studies have shown independent effects...
2.
Pietrantonio F, Yaeger R, Schrock A, Randon G, Romero-Cordoba S, Rossini D, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-11.
PMID: 35100719
Purpose: To describe the clinical and molecular features of metastatic colorectal cancers (mCRCs) bearing uncommon atypical (At-) mutations at codons other than 12, 13, 59, 61, 117, and 146. Materials...
3.
Romero-Cordoba S, Tagliabue E, Triulzi T, Bianchi F
JCO Precis Oncol
. 2022 Jan;
4:1267-1268.
PMID: 35050784
No abstract available.
4.
Garcia-Olivares M, Romero-Cordoba S, Ortiz-Sanchez E, Garcia-Becerra R, Segovia-Mendoza M, Rangel-Escareno C, et al.
J Steroid Biochem Mol Biol
. 2021 Feb;
209:105831.
PMID: 33582304
Calcitriol and transforming growth factors beta (TGF-β) are involved in several biological pathways such as cell proliferation, differentiation, migration and invasion. Their cellular effects could be similar or opposite depending...
5.
Cosentino G, Romero-Cordoba S, Plantamura I, Cataldo A, Iorio M
Cells
. 2020 Sep;
9(9).
PMID: 32972039
Tumor growth and invasion occurs through a dynamic interaction between cancer and stromal cells, which support an aggressive niche. MicroRNAs are thought to act as tumor messengers to "corrupt" stromal...
6.
Navarrete-Bernal M, Cervantes-Badillo M, Martinez-Herrera J, Lara-Torres C, Gerson-Cwilich R, Zentella-Dehesa A, et al.
Front Oncol
. 2020 Aug;
10:1206.
PMID: 32850353
Patients with triple-negative breast cancer (TNBC) have a poor prognosis, partly because of the absence of targeted therapies. Recognition of the key role of immune responses against cancer has allowed...
7.
Cataldo A, Romero-Cordoba S, Plantamura I, Cosentino G, Hidalgo-Miranda A, Tagliabue E, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32806777
: Chemotherapy is still the standard of care for triple-negative breast cancers (TNBCs). Here, we investigated miR-302b as a therapeutic tool to enhance cisplatin sensitivity in vivo and unraveled the...
8.
Cedro-Tanda A, Rios-Romero M, Romero-Cordoba S, Cisneros-Villanueva M, Rebollar-Vega R, Alfaro-Ruiz L, et al.
Sci Rep
. 2020 Aug;
10(1):13146.
PMID: 32753692
Breast cancer is the most commonly diagnosed neoplasm in women worldwide with a well-recognized heterogeneous pathology, classified into four molecular subtypes: Luminal A, Luminal B, HER2-enriched and Basal-like, each one...
9.
Romero-Cordoba S, Meneghini E, Sant M, Iorio M, Sfondrini L, Paolini B, et al.
Cancers (Basel)
. 2019 Jul;
11(7).
PMID: 31261762
Triple negative breast cancer (TNBC) is an aggressive subtype with limited therapeutic options. New opportunities are emerging from current comprehensive characterization of tumor immune infiltration and fitness. Therefore, effectiveness of...
10.
Borgonio-Cuadra V, Valdez-Vargas C, Romero-Cordoba S, Hidalgo-Miranda A, Tapia-Guerrero Y, Cerecedo-Zapata C, et al.
Mol Neurobiol
. 2019 Feb;
56(9):6106-6120.
PMID: 30721448
Spinocerebellar ataxia type 7 (SCA7), a neurodegenerative disease characterized by cerebellar ataxia and retinal degeneration, is caused by a CAG repeat expansion in the ATXN7 gene coding region. Disease onset...